Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585191 | 1.00 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL1527541 | 1.00 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL2816370 | 1.00 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL29271053 | 1.00 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL2400621 | 1.00 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL1227289 | 0.98 | PPARD (0.52) | PPARDTSHR | |
| Hydrochloric Acid SCHEMBL4879960 | 0.96 | PPARD (0.50) | PPARDTSHR | |
| SCHEMBL321312 | 0.91 | PPARD (0.54) | PPARDTSHR | |
| SCHEMBL7268183 | 0.89 | PPARD (0.61) | PPARDTSHR | |
| SCHEMBL11514496 | 0.89 | PPARD (0.61) | PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-4229059-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022079245-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079245-A1 | 3-SUBSTITUTED XANTHINE DERIVATIVES AS MRGPRX4 RECEPTOR MODULATORS | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2022-04-21 | — | — | WO | disclosed |
| US-9950062-B2 | Compounds and compositions as TLR activity modulators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-04-24 | — | — | US | disclosed |
| US-9861557-B2 | Dental materials on the basis of urea group-containing monomers | IVOCLAR VIVADENT AG (LI) | 2018-01-09 | — | — | US | disclosed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20160151249-A1 | DENTAL MATERIALS ON THE BASIS OF UREA GROUP-CONTAINING MONOMERS | IVOCLAR VIVADENT AG (LI) | 2016-06-02 | — | — | US | disclosed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9045470-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2015-06-02 | — | — | US | disclosed |
| EP-2473508-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2012-07-11 | — | — | EP | disclosed |
| EP-2459216-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | Novartis AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011049677-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011027222-A2 | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | PPARD 256/4885TSHR 3415/4885 |
| US-20240002416-A1 | MRGPRX4 Agonists and Antagonists | MRGPRX4, MRGPRX1, MRGPRX2 | PPARD 1019/4885TSHR 630/4885 |
| US-20110053893-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | PPARD 256/4885TSHR 3415/4885 |
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | PPARD 893/4885TSHR 2380/4885 |
| US-20160151249-A1 | DENTAL MATERIALS ON THE BASIS OF UREA GROUP-CONTAINING MONOMERS | UFM1, SLC14A1, USO1 | PPARD 4553/4885TSHR 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.